Oncopeptides AB has withdrawn melphalan flufenamide or melflufen (Pepaxto) from the market in the United States, after results from the phase 3 OCEAN study showed the drug had a negative effect on overall survival.
The drug had been granted accelerated approval on Feb. 26, 2021, for use in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma (MM) who had received at least four previous lines of therapy, and whose disease was refractory to at